Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002818 | 1.00 | TRPV4 (0.66) | TRPV4KDM4EPKMTSHRSMN1; SMN2 | |
| SCHEMBL1127669 | 0.85 | KDM4E (0.59) | TRPV4KDM4ETSHRSMN1; SMN2HTT | |
| SCHEMBL27589372 | 0.81 | KDM4E (0.47) | TRPV4KDM4EPKMTSHRSMN1; SMN2 | |
| SCHEMBL28755848 | 0.81 | TSHR (0.52) | KDM4EPKMTSHRSMN1; SMN2HTT | |
| SCHEMBL5406327 | 0.81 | TRPV4 (0.61) | TRPV4KDM4ETSHRHTTALDH1A1 | |
| SCHEMBL533956 | 0.79 | TRPV4 (0.68) | TRPV4KDM4EPKMTSHRSMN1; SMN2 | |
| SCHEMBL29482639 | 0.79 | TRPV4 (0.68) | TRPV4ALDH1A1CYP1A2CYP3A4ALPL | |
| SCHEMBL29420268 | 0.79 | TRPV4 (1.00) | TRPV4KDM4ETSHRMEN1ALDH1A1 | |
| SCHEMBL2947794 | 0.79 | TRPV4 (1.00) | TRPV4KDM4ETSHRMEN1ALDH1A1 | |
| SCHEMBL74997 | 0.79 | TRPV4 (0.68) | TRPV4ALDH1A1CYP1A2CYP3A4ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428376-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240360083-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2024-10-31 | — | — | US | disclosed |
| CN-117858879-A | CDK2/4/6 inhibitor and preparation method and application thereof | 南京再明医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11866411-B2 | Therapeutic compounds and compositions | Agios Pharmaceutical, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3094325-B1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-10-13 | — | — | EP | disclosed |
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-10988448-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3708169-A1 | 2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | Agios Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3241554-B1 | QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | AGIOS PHARMACEUTICALS INC (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| WO-2015108861-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20140323467-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8785450-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2448582-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Agios Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011002817-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | TRPV4 2256/4885KDM4E 2557/4885PKM 4195/4885 |
| US-10988448-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | TRPV4 2757/4885KDM4E 766/4885PKM 6/4885 |
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | TRPV4 2757/4885KDM4E 766/4885PKM 6/4885 |
| US-12428376-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | TRPV4 2757/4885KDM4E 766/4885PKM 6/4885 |
| US-20240360083-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | TRPV4 2757/4885KDM4E 766/4885PKM 6/4885 |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | TRPV4 2757/4885KDM4E 766/4885PKM 6/4885 |
| US-20140323467-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | TRPV4 2757/4885KDM4E 766/4885PKM 6/4885 |
| US-11866411-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | TRPV4 2757/4885KDM4E 766/4885PKM 6/4885 |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | TRPV4 2635/4885KDM4E 1579/4885PKM 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.